OR WAIT null SECS
March 08, 2024
EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.
March 07, 2024
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
March 06, 2024
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 02, 2024
Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.
February 28, 2024
Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.
February 27, 2024
The agency has recommended granting marketing authorization to ALS treatment, Qalsody (tofersen), for adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.
February 23, 2024
Steffen Thirstrup, chief medical officer of the EMA, discusses manufacturing supply, drug shortages, commercial incentives, politics, and patient wellbeing.
February 21, 2024
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
February 16, 2024
Two public electronic catalogues will be available for real-world data sources and for real-world data studies.